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Interleukin-28B (IL28B) polymorphisms have previously been reported to be strongly associated with
spontaneous and treatment-induced HCV viral clearance.
Aim: To assess the impact of four different IL28B polymorphisms and their haplotype combination and
interferon-c inducible protein 10 (IP-10) in response to treatment in Egyptian genotype 4 patients.
Method: 159 HCV-genotype 4 patients were included. All patients were treated with Peginterferon
alph2a/Ribavirin for 48 wk. The following polymorphisms rs12979860, rs11881222, rs8103142 and
rs8099917 and rs80803142 of Il-28 were known to be associated with the sustained virological response.
They were genotyped using the TaqMan assay. IP-10 was assessed by Eliza.
Results: The data indicated that all SNPs are within the Hardy-Weinberg Equilibrium (HWE) except for
rs8103142 (p¼6.2559), therefore it was excluded from the study since it deviates from HWE-P. The CC,
AA and TT genotypes of rs12979860, rs11881222 and rs8099917 were the more frequent genotypes
among the responders at RVR, EVR, ETR and SVR, respectively. The frequency of CC, CT, and TT genotype
was 46.4%, 38.1% and 15.5% among responders of RVR, and was 46.9%, 45.9% and 7.2 among responders of
SVR for rs12979860, respectively. The relapse rate was 18.0% and 16.0 % during EVR and ETR, while the
response rate was 52.8%, 58.5%, 59.7% and 61.6% after 4, 12, 48 and 72 weeks of treatment. The transient
virological response (TVR) was 6.9% among HCV patients. The results showed that the odds ratio and 95%
CI of HCV genotype 4 patients to have a better sustained response to treatment (SVR) was 2.92, (1.83–
4.68, p¼2.015), 2.89 (1.79–4.70, p¼2.535), and 2.73 (0.21–0.65, p¼0.0007) for those with the major
allele “C” of rs12979860, the “A” allele of rs11881222, and the “T” allele of rs8099917, respectively.
Furthermore, the positive predictive value (PPV) of the major homozygous alleles for SVR with better
response to therapy was in the following order: 78.69%, 68.42%, and 32.14% with a positive likelihood
ratio of 1.95, 1.25, and 0.86 for rs12979860, rs11881222 and rs8099917, respectively. The haplotype
formed between the 3 studied SNPs (rs12979860, rs11881222 and rs8099917) showed that two
haplotypes (TGG and TGT) increased the probability of a poor response to therapy, but the CAT haplotype
had the opposite effect. Multinomial logistic regression analysis revealed that the viral load and
rs12979860 are the only signiﬁcant actors involved in the efﬁcacy of the treatment response among
the cohort study. In addition, patients with SVR had signiﬁcantly lower values of IP-10 than non-
responder patients (NR), with a P-valueo¼0.001.
Conclusions: In genotype 4 cases, the IL28B SNPs rs12979860 rs8099917, and rs11881222 are the
strongest predictors of a response, while IP-10 is a strong negative biomarker of a response. Accounting
for this factor is important in the individualization of treatment and enhances the degree of
predictiveness of the IL28 polymorphism in the ﬁnal treatment outcome. The frequent distribution of
C, A and T alleles of IL28 polymorphism are higher among TVR, which may reﬂect sensitivity to
prolonged course.
& 2013 Published by Elsevier Inc.lsevier Inc.
oenterology and Hepatology
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Fig. 1. Linkage Disequilibrium of the rs12979860, rs11881222 and rs8099917 of
IL-28 B gene in chronic hepatitis patients C under treatment. Footnote: Red diamonds
represents pairwise LD “EM D” values between rs12979860, and rs11881222 (upper
left), rs11881222 and rs8099917 (upper right), and rs12979860, and rs8099917
(lower), respectively.
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The hepatitis C virus (HCV) genotype is an important predictor
of disease progression and treatment response. Genotype 1b has a
worldwide distribution and is often found to be the most common
genotype. HCV-genotype 4 causes approximately 20% of the 180
million cases of chronic hepatitis C in the world, is predominant in
the Middle East and Northern Africa, and has recently spread to
Southern Europe (Fernandez-Arcas et al., 2006). Genotype
4 accounts for more than 90% of the reported cases from Egypt,
a country with a massive HCV-related disease burden (Kamal and
Nasser, 2008). However, knowledge of factors predicting sensitiv-
ity to combined antiviral treatment is still limited and restricted in
populations infected with HCV-4.
Many viral and host factors have been investigated as pre-
dictors for achieving viral clearance. Higher age, advanced liver
ﬁbrosis, and diabetes have been shown to signiﬁcantly reduce the
response rates in patients infected with HCV-4, and Egyptian
ethnicity has been claimed to be a positive predictor of a sustained
virological response (Papastergiou et al., 2012) that is not related
to insulin resistance (Cieśla et al., 2012). Serum adiponectin at
baseline levels appears to be an independent predictor in the
achievement of SVR in Genotype 4 (Derbala et al., 2009).
Recently, viral genetic polymorphisms, especially within the
core and NS5A regions, have been shown to affect the response to
treatment in HCV-4 infection (El-Shamy et al., 2012). Differences in
host genetics are believed to inﬂuence the outcome of hepatitis C
virus (HCV) infection. The interleukin 28B (IL28B) variability has a
strong impact on viral clearance, either spontaneously or drug-
induced, in HCV infected patients. Moreover, several recent ﬁnd-
ings have demonstrated that some SNPs in the IL28B gene are
closely associated with pegylated-interferon (Peg-IFN)/Ribavirin
responsiveness, but the true mutation has not been identiﬁed yet.
Therefore, new SNPs still need to be discovered. In total, 20
polymorphisms of IL28B have been studied in HCV genotype 1;
however, very few reports have been published on Genotype 4.
The CC genotype of the IL28B SNP was found to be associated
with higher sustained virological response (SVR) rates than the TT
or TC genotypes across all population groups (Ge et al., 2009b).
The magnitude of this association between the CC genotype and
SVR was greater than that of other clinical factors currently used to
predict treatment responses in patients infected with genotype
1 HCV, including baseline viral load, baseline ﬁbrosis, and ethnicity
(McCarthy et al., 2010). Additionally, the expression of this SNP at
the mRNA level was signiﬁcantly reduced in the chronically
infected cohort compared with ethnically matched controls, which
reﬂects the relationship between the C allele and the natural
clearance of HCV (Shi et al., 2012).
Among Egyptians, who have the highest prevalence of Geno-
type 4 worldwide, HCV clearance has been associated with a
region of IL28B that is smaller compared to European populations,
involving the non-synonymous IL28B SNP rs8103142 (Pedergnana
et al., 2012). Inheritance of the IL4 polymorphism may be asso-
ciated with resistance to combined antiviral therapy in Egyptian
HCV patients (Shalaby et al., 2012). In addition, a strong associa-
tion between the intracellular adhesion molecule-1 gene marker
rs281437 and the progression of hepatic ﬁbrosis has been
reported, but not a response to treatment (Rizk and Derbala, 2012).
Abnormal cytokine levels may contribute to viral persistence
and may affect the response to antiviral therapy. Serum IL-10,
IL-12, and IL-18 levels are predictive of the response to HCV
treatment of HCV-genotype 1 (Yoneda et al., 2011). Few studies
have investigated the relationship between cytokines and
response to treatment in genotype 4. The interferon-c inducible
protein 10 (IP-10, CXCL10) has been proven to be a valid biomarker
associated with HCV ﬁbrosis (Romero et al., 2006). IP-10 issecreted into the blood by HCV infected hepatocytes and therefore
can be used as a direct indicator of ongoing inﬂammation in the
liver (Li et al., 2012). The impact of IP-10 on the elimination of HCV
RNA in genotype 4 Egyptian patients during therapy under IL28B
genetic variant conditions is not known.
The aim of this study was to assess the effect of four different
IL28B polymorphisms (rs12979860, rs8099917, rs11881222 and
rs.81803142) on the sustained virological response (SVR) to
genotype 4 and the effect of haplotype combination of these
polymorphisms on viral clearance. The rational for choosing the
SNPs rs12979860, rs8099917, rs11881222 and rs.81803142, were
based on previous published reports of their relation to SVR by
Ito et al. (2011), Tanaka et al. (2009), Ge et al. (2009b), Shi et al.
(2012). Furthermore, we assessed plasma IP-10 in relation to
genetic variants and their impact on viral clearance in response
to treatment.Results
Clinical and biochemical data of HCV patients (Table 1, Fig. 1)
Among 159 patients, 98 patients achieved the SVR with a ratio
of 61.6%. The mean age of all patients was 46.4778.83 years, and
91% were males. The non-responders had signiﬁcantly higher
levels of pre-treatment AST, viral load at 4 weeks of treatment
and stages of inﬂammation (mild and severe) compared to the
responders (SVR) group. No signiﬁcant difference was found
between SVR and NR for age, BMI, pre-ALT, pre-albumin, pre-
total bilirubin, white blood cell and platelet count before the
treatment and the degree of ﬁbrosis, as shown in Table 1.
In addition, overall the SNP genotypes and allelic frequencies
were determined in 159 individuals. Filtering the SNPs in this
study was performed by a call rate o90.0% and if the Hardy-
Weinberg Equilibrium (HWE) was o0.005 among populations.
Table 1
Demographic and biochemical data among all study patients and on basis of their response to treatment by the antiviral therapy as sustained virological responders (SVR)
and non-responders (non-SVR and relapse).
Variables All study subjects Responders (N¼98) Non-responders (N¼61) P value
Age (years) 46.47 (8.83) 45.81(8.88) 47.52 (8.69) 0.237
Gender (Males)/(Females) 144/15 (91.0%/9.0%) 86/12 (12.24/87.76%) 3/58 (4.92/95.08%) 0.124
BMI (kg/m2) 30.18 (5.05) 30.53 (5.74) 29.62 (3.63) 0.289
LFT (pre-treatment)
Pre-ALT (U/L)n 51.00 (34.00–87.00) 47.50 (30.00–87.00) 56.00(40.00–90.00) 0.089
Pre-AST (U/L)n 38.00 (27.00–50.75) 35.00 (26.00–47.25) 42.00 (32.00–63.50) 0.021
Pre-treatment viral load (copies/ml)n 449165.50 (21861.50–2116677.50) 174991.0 (3842.0–719013.0) 710476.0 (463008.0–2835489.0) o0.001
Viral load at 4 weeks (copies/ml) 148001.99 (508930) 21253.98 (10139.84) 588602.19 (95126.63) o0.001
Pre-total WBC (103 /ml)n 2.80 (1.78–3.60) 2.60(1.70–3.70) 2.85 (1.80–3.60) 0.679
Pre- platelet count (105/ml) 190.00 (155.50–228.00) 193.00 (152.50–231.50) 188.90 (158.50–226.50) 0.688
Degree of ﬁbrosis (n, %)
Mild 109 (68.55%) 71 (72.45%) 38 (62.29%) 0.214
Severe 50 (31.45%) 27 (17.55%) 23 (37.71%)
Inﬂammation grades (n, %)
Mild 112 (70.44%) 77 (78.57%) 35 (57.38%) 0.017
Severe 47 (29.56%) 21 (21.43%) 26 (42.62%)
rs12979860
CC 57 (35.8) 46 (46.9) 11 (18.0) 0.0001
CT 77 (48.4) 45 (45.9) 32 (52.5)
TT 25 (15.8) 7 (7.2) 18 (29.5)
C 0.6 0.69 0.44
rs11881222
AA 64 (40.2) 49 (48.9) 15 (22.0) 0.0001
AG 75 (47.2) 43 (41.8) 32 (54.3)
GG 20 (12.6) 6 (4.3) 14 (23.7)
A 0.64 0.72 0.5
rs8099917
GG 8 (5.0) 3 (3.1) 5 (8.2) 0.004
GT 55 (34.6) 26 (26.5) 29 (47.5)
TT 96 (60.4) 69 (70.4) 27 (44.3)
T 0.78 0.84 0.68
Continuous data are presented as means (SD) for normally—distributed data and as nmedian and interquartile for non-distributed data. Categorical data are presented as
number and (percentage). Two-tailed P value is signiﬁcant o0.05. Abbreviations: BMI, body mass index; LFT, liver function tests; Pre, pre-treatment; Pre-ALT, pre-treatment
Alanine Aminotransferase; Pre-AST, pre-treatment Aspartate Aminotransferase; and WBC, White Blood Cells count.
Table 2
Genotype distribution among rs12979860, rs11881222, and rs8099917 at 4 weeks
(RVR), 12 weeks (EVR) and 48 weeks (ETR) of treatment.
Genotype RVR EVR ETR
R NR R NR R NR
rs12979860 (N¼84) (N¼75) (N¼93) (N¼66) (N¼95) (N¼64)
CC 39 (46.4) 18 (31.6) 45 (48.4) 12 (18.2) 44 (46.3) 13 (20.3)
CT 32 (38.1) 45 (58.4) 41 (44.1) 36 (54.5) 44 (46.3) 33 (51.6)
TT 13 (15.5) 12 (16.0) 7 (7.5) 18 (27.3) 7 (7.4) 18 (28.1)
P value 0.008 0.0001 0.0001
rs11881222 (N¼84) (N¼75) (N¼93) (N¼66) (N¼95) (N¼64)
AA 41 (48.8) 21 (28.0) 43 (46.2) 19 (28.8) 44 (46.3) 17 (26.6)
AG 31 (36.9) 44 (58.7) 41(44.1) 34 (51.5) 43 (45.3) 32 (50.0)
GG 12 (14.3) 10 (13.3) 9 (9.7) 13 (19.7) 8 (8.4) 15 (23.4)
P value 0.004 0.033 0.0008
rs8099917 (N¼84) (N¼75) (N¼93) (N¼66) (N¼95) (N¼64)
GG 5 (6.0) 5 (6.7) 5 (5.4) 5 (7.6) 4 (4.2) 7 (10.9)
GT 27 (31.1) 26 (34.7) 23 (24.7) 32 (48.5) 24 (25.3) 30 (46.9)
TT 52 (61.9) 44 (58.7) 65 (69.9) 29 (43.9) 67 (70.5) 27 (42.2)
P 0.879 0.005 0.0003
Categorical data are presented as number and (percentage). Two-tailed P value is
signiﬁcant o0.05.
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(p40.005), except for rs8103142, where the HWE was
1.3991013 and 0.0003 among the control (SVR) and active
cases (NR), respectively. Therefore, rs8103142 was not included in
this study. A signiﬁcant difference was observed in the genotypic
distribution of rs12979860, rs11881222 and rs8099917 between
the SVR and NR subjects as shown in Table 1. The frequency (%) of
the major alleles for all studied SNPs is presented in Table 1.
Utilizing the logistic regression analysis, the odds ratio and 95% CI,
after multiple test corrections for FDR and Bonferroni adjustments
of SNPs numbers, between SVR and NR was 2.92 (1.83–4.68,
p¼2.015), 2.89 (1.79–4.70, p¼2.535) and 2.73 (0.21–0.65,
p¼0.0007) for the major allele “C” of rs12979860, the “A” allele
of rs11881222, and the “T” allele of rs8099917, respectively.
Genotype distribution of rs12979860 (C/T), rs11881222 (A/G), and
rs8099917 (G/T) of the IL-28B gene between responders [R] and non-
responders [NR] during (RVR), (EVR) and (ETR) in chronic hepatitis C
patients genotype 4 under treatment (Table 2)
A signiﬁcant difference was observed in the genotypic distribu-
tion of rs12979860, and rs11881222 between responders and
non-responders for RVR, EVR and ETR with P values o0.005.
In addition, the homozygous CC and AA genotypes are the most
frequent genotype observed in responders during RVR, EVR
and ETR.
The homozygous TT genotype is the most frequent genotype
among RVR, EVR and ETR for rs8099917 polymorphism. A sig-
niﬁcant difference was observed in the genotypic distribution of
rs8099917 between responders and non-responders for EVR andETR with P values o0.005. Of note, the heterozygote genotype CT,
AG and GT are the most frequent observed among non –respon-
ders during RVR, EVR and ETR for rs12979860 (C/T), rs11881222
(A/G), and rs8099917 (G/T), respectively. In addition, the likelihood
ratios between RVR and SVR was 7.087, p¼0.008 by chi-square
test.
Table 3
Relapse rate in count and in percentage and its genotype distribution among HCV
patients at 12 (EVR), 48 (ETR) and 72 (SVR) weeks of treatment.
EVR relapse ETR relapse TVR
Relapse rate (N¼28, 18.0%) (N¼25, 16.0%) (N¼11, 6.92%)
rs12979860
CC 5 (17.9) 7 (28.0) 3(27.3)
CT 15 (53.6) 15 (60.0) 5(45.4)
TT 8 (28.5) 3 (12.0) 3(27.3)
P value 0.031 0.449 0.571
rs11881222
AA 7.0 (25.0) 7.0 (28.0) 4.0 (36.2)
AG 14.0 (50.0) 14.0 (56.0) 5.0 (45.4)
GG 7.0 (25.0) 4.0 (16.0) 2.0 (18.2)
P value 0.185 0.671 0.795
rs8099917
GG 1.0 (3.6) 3.0 (12.0) 2.0 (18.2)
GT 15.0 (53.6) 10.0 (40.0) 4.0 (36.2)
TT 12.0 (42.8) 12.0 (48.0) 5.0 (45.4)
P value 0.048 0.077 0.795
Categorical data are presented as number and (percentage). Two-tailed P value is
signiﬁcant o0.05.
Table 4
Odds ratio (OR), 95% conﬁdence interval with P value of Il-28 polymorphisms;
rs12979860, rs11881222, and rs8099917 of IL-28 B gene among sustained virolo-
gical responders (SVR) and non-responders (NR) in chronic hepatitis patients
C-genotype 4 under treatment.
Polymorphism SVR Vs. NR Genotype
(models)
Adjusted odds ratio
(95% CI)
P
value
rs12979860 CC+TC/TT 15.05 (2.83–22.92) 0.000
CC/TC+TT 5.13 (2.07–12.75) 0.000
CC/TT 18.24 (5.17–64.42) 0.000
CC/CT 3.75 (1.37–9.22) 0.009
CT/TT 5.13 (1.72–15.28) 0.003
rs11881222 AA+AG/GG 14.97 (3.76–59.298) 0.000
AA/AG+GG 4.90 (2.13–11.29) 0.000
AA/GG 31.87 (7.03–144.38) 0.000
AA/AG 3.80 (1.46–8.35) 0.005
AG/GG 9.11(2.21–37.62) 0.002
rs8099917 GG+GT/TT 12.80 (1.87–227.44) 0.014
GG/ GT+TT 4.15 (1.88–9.19) 0.000
GG/TT 12.48 (3.08–505.99) 0.005
GG/GT 3.86 (1.59–8.11) 0.002
GT/TT 11.0 (0.86–141.07) 0.065
Adjusted odds ratios (aORs), 95% Conﬁdence Intervals (CIs), and P values were tested
using logistic regression. aORs was adjusted for age, BMI, pre-treatment viral load,
ﬁbrosis and pre-ALT, using the recessive, dominant and additive genetic models for
rs12979860, rs11881222 and rs8099917, respectively). SVR¼sustained virological
response and NR¼non-responders. Two-tailed P value is signiﬁcant&0.05.
Table 5
The positive predictive values for the major allele and the homozygous of the major
alleles for better treatment response (SVR) versus non-SVR after follow up of
complete treatment.
Polymorphism Major allele
PPV 95% conﬁdence
intervals & +LR
Major homozygous allele
PPV 95% conﬁdence
intervals& +LR
rs12979860 C/T 71.73% (64.77%–77.99%) 78.69% (66.32–88.14%)
+LR 1.58 1.95
rs11881222 A/G 70.26% (63.31%–76.85%) 68.42% (54.76%—80.09%)
+LR 1.5 1.25
rs8099917 G/T 57.23% (49.49%-64.71%) 32.14% (15.88%-52.35%)
+LR 0.81 0.86
Data are evaluated by 22 tables with ﬁsher exact test and presented as %.
PPV¼probability that the disease is present when the test is positive, and +LR,
positive likelihood ratio. The major alleles are C, A and T for rs12979860,
rs11881222 and rs8099917, respectively. Abbreviations: PPV, positive predictive
value; LR, positive likelihood ratio (see statistical analysis).
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early virological response, end of treatment response and transient
virological response (Table 3)
Table 3 highlights the relapse rate and the genotype distribu-
tion among HCV patients who received pegylated interferon and
oral ribavirin for 48 weeks. Of note the relapse rate decreases from
18.0% in EVR to 16.0% in ETR, while TVR was 6.92% among the
study subjects. Furthermore, the genotype distribution among
patients who had EVR and ETR shows that the heterozygous
groups of rs12989860 (CT), and rs11881222 (AG) are the most
frequent pattern seen. Among TVR subjects, the most frequent
genotype seen among these patients are CT, AG and TT for
rs12979860, rs11881222 and rs8099917, respectively. No signiﬁ-
cant difference was observed among the genotype distribution for
rs12979860, rs11881222 and rs8099917 among EVR, ETR and TVR
(p 40.05)
Association between SVR and Il-28 B gene polymorphisms
(rs12979860, rs11881222 and rs8099917) based on genetic
models (Table 4)
Using the genetic model (CC+TC/TT) for rs12979860, the
carriers of all C alleles (CC+CT) had an increase of ∼15-fold (OR,
(95% CI)¼15.05 (2.83–22.92), p¼0.0001) in the odds of the
clearance rate of HCV in response to treatment compared with T
allele carriers. Moreover, using the genetic model (CC/TC+TT), the
CC genotype had a marked signiﬁcant effect on treatment
response events by odds of 5.13-fold (95% CI¼2.07–12.75,
p¼0.000), as shown in Table 2. Using the genetic model (AA
+AG/GG) for rs11881222, carriers of all A alleles (AA+AG) had an
increase of ∼15-fold (95% CI¼3.76–59.298, p¼0.000) in the clear-
ance rate of HCV in response to treatment compared with G allele
carriers. Additionally, using the genetic models (AA/AG+GG), the
AA genotype clearly had a signiﬁcant effect on treatment response
events by ∼5-fold (95% CI¼2.13–11.29, p¼0.000) after adjustment
of the OR, as shown in Table 2. Using the genetic model (GG+GT/
TT) for rs8099917, carriers of all G alleles (GG+GT) had an increase
of ∼13-fold (OR 12.80, 95% CI¼1.87–227.44, p¼0.014) in the
clearance rate of HCV in response to treatment compared with T
allele carriers. Furthermore, using the genetic model (GG/GT+TT),
the GG genotype had a remarkably signiﬁcant effect on treatment
response events by odds of 4.15-fold (95% CI¼1.88–9.19),
p¼0.000), as shown in Table 2.The positive predictive value of rs12979860, rs11881222 and
rs8099917 among treated HCV patients in response to therapy
with higher clearance rates (Table 5).
The positive predictive value (PPV) of the major alleles for SVR
with enhanced response to therapy were in the order of 71.73%,
70.26%, and 57.23% with positive likelihood ratios (+LR) of 1.58, 1.50,
and 0.81 for rs12979860, rs11881222 and rs8099917, respectively. The
PPV of the major homozygous alleles for SVR with enhanced response
to therapy were in the order of 78.69%, 68.42%, and 32.14% with
positive likelihood ratios (+LR) of 1.95, 1.25, and 0.86 for rs12979860,
rs11881222 and rs8099917, respectively (Table 3).
Linkage disequilibrium (LD) of the three Il-28 B gene polymorphism
SNPs (rs12979860, rs11881222 and rs8099917) in HCV patients
(Fig. 1)
Pairwise LD between the 3 polymorphisms was evaluated using
data from all subjects. Using the expectation-maximization (EM),
the results of LD and the r2 for all study subjects are presented in
Table 6
Haplotype frequency of the rs12979860, rs11881222 and rs8099917polymorphisms of IL-28B gene and its associations with the poor treatment response in HCV patients
for (NR) Vs. (SVR) outcome.
rs12979860 C rs12979860/Tr rs11881222/Ar rs11881222/G rs8099917/G rs8099917/T Haplotype EM frequency
(SVR)
EM frequency
(NR)
Adjusted odds ratio,
95% Cl
P value
C T A G G T CAG 0.667 0.395 0.33 (0.19–0.53) 9.586
C T A G G T TGT 0.112 0.287 3.27 (1.75–6.12) 0.0001
C T A G G T TGG 0.111 0.202 2.08 (1.08–4.05) 0.027
C T A G G T TAT 0.053 0.059 1.70 (0.42–3.28) 0.765
C T A G G T CGT 0.028 0.018 0.62 (0.12–3.27) 0.575
C T A G G T CAT 0.020 0.013 0.66(0.09–4.55) 0.667
Data are presented as frequency for SVR and NR for each haplotype with the odds ratio, lower and upper 95% conﬁdence intervals and P value. The data were analyzed by
logistic regression analysis. aORs was adjusted for age, BMI, pre-treatment viral load, ﬁbrosis and pre-ALT. SVR¼sustained virological response and NR¼non-responders.
Two-tailed P valueis signiﬁcant & 0.05.
Table 7
Logistic regression analysis of the factors involved in the efﬁcacy of therapy
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highest LD in the study subjects.response (SVR Vs. NR) in all chronic hepatitis C patients.
Regressor B
Coefﬁcient
Std.
error
P
value
Odds
ratio
Lower conf.
interval
Upper conf.
interval
Age 0.011 0.021 0.607 1.01 0.968 1.055
BMI 0.038 0.078 0.627 1.039 0.486 1.763
Fibrosis 1.031 0.704 0.138 2.804 0.705 11.151
Pre-ALT 0.007 0.009 0.429 1.007 0.989 1.026
Viral load-
basic
0.793 0.397 0.043 2.212 1.014 4.823
rs12979860 0.880 0.447 0.036 2.413 1.015 5.793
rs11881222 0.575 0.426 0.177 1.771 0.771 4.100
rs8099917 0.249 0.432 0.562 1.283 0.550 2.994
Data are presented as b- coefﬁcient, standard error, the odds ratio, lower and upper
95% conﬁdence intervals and P value. The data were analyzed by logistic regression
analysis. SVR¼sustained virological response and NR¼non-responders. Two-tailed
P value is signiﬁcant &0.05.Haplotype frequency and its association with poor therapy response
among HCV patients under treatment (Table 6)
The alleles (rs12979860, rs11881222 and rs8099917) of the
Il-28 B gene formed several frequent haplotypes, as shown in
Table 4. Only the CAT haplotype has a signiﬁcant protective effect
against poor response to therapy by 67%, and its frequency in SVR
is nearly 1.7 times its frequency in NR (66.7% vs. 39.5%, p¼9.586).
Alternatively, the two haplotypes TGG and TGT signiﬁcantly
increase the odds of a poor therapy response by 3.27- (95%
CI¼1.75–6.12) and 2.08-fold (95% CI¼1.08–4.05) in HCV patients
receiving the treatment, respectively. Their frequencies in NR were
28.7% and 20.2%, which were nearly double its frequency in SVR
(11.2% and 11.1%) for TGG and TGT, respectively.Multi-logistic regression analysis to assess the factors involved
in the efﬁcacy of treatment response (Table 7)
The multinomial regression analysis was performed to discri-
minate the signiﬁcant effect of the following independent
variables: age above 45 years, body mass index above 30 kg/m2,
pre-ALT, liver ﬁbrosis, basic level of the viral load, and the three
SNPs (rs12979860, rs11881222 and rs8099917) in their additive
models on the dependent factor, which is the rate of the clearance
response (SVR vs. NR). After normalizing for these factors, only the
rs12979860 SNP and baseline viral load were still signiﬁcantly
associated with SVR. The odds of having a better response and
clearance of the HCV after treatment was 2.41- and 2.2-fold for
rs12979860 and pre-treatment viral load with P-values of 0.036
and 0.034, respectively, as shown in Table 5.IP-10 and its association with genotype distribution and response
to treatment (Fig. 2)
The median and the interquartile values for IP-10, based on the
genotype distribution and response to treatment, are presented in
Fig. 2a–d. Patients carrying the T allele of rs12979860, the G allele
of rs11881222 and the G allele of rs8099917 exhibited greater
signiﬁcant values compared to C, A and T allele patient carriers,
respectively (Fig. 2a). The median and the interquartile values for
IP-10 based on the treatment response (SVR and non-SVR) are
presented in Fig. 2d. Non-responders to treatment (NR) had
signiﬁcantly higher values of IP-10 than responder patients
(SVR), with a P-valueo¼0.001 (Fig. 2d).Discussion
Pegylated-interferon-a and ribavirin still maintain pivotal roles
in the management of chronic HCV-Genotype 4. Thus, the predic-
tion of a patient's response is important to reduce adverse effects
and expenses.
Genome-wide association studies have identiﬁed polymorph-
isms located near the gene encoding IL28B, which was discovered
to be the best predictor of patient response to pegylated-
interferon plus ribavirin for chronic hepatitis C virus (HCV)
genotype 1 infection.
In support of the current data that CC genotype of rs12979860
was the predominant allele among our Egyptian study group, a
recent study by El-Awady et al. (2012) demonstrated the Genotype
C/C is the prominant genotype . These data may explain the higher
response rate among Egyptians Genoptype4 compared to western
reports. El-Ewady screened his patients for rs12979860 poly-
morphism only and this may explain higher prevelance of the
favroble TT genotype of SNP rs8099917 among our patient
In 2009, Ge et al. (2009b), along with subsequent studies in
European and American cohorts, demonstrated a stronger associa-
tion between SVR rates and the C/C genotype of rs12979860 in
HCV-genotype 1 (McCarthy et al., 2010). However, the IL-28B
genotype did not predict the outcomes in individual groups based
on prior treatment response and only plays a minor role when on-
treatment viral responses are taken into consideration (Liu et al.,
2012). Additionally, an rs8099917 T/T variant has been reported to
be an independent predictor of SVR in Genotype-1 patients
(Miyamura et al., 2012).
In ﬁve studies, patients reported to be monoinfected with HCV
were studied: 102 cases from Austria (97% of them were Egyp-
tians) (Stattermayer et al., 2011), 103 patients from Milan, Italy
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Fig. 2. Serum IP-10 level based upon genotype distribution, of rs12979860 (3 A), rs11881222 (3B) and rs8099917 (3c) of IL-28 B gene, and upon sustained response to treatment
(SVR vs. NR), (3d) in chronic hepatitis patients C under treatment. (a) IP-10 and genotypes of rs12979860, (b) IP-10 and genotypes of rs11881222, (c) IP-10 and genotype of rs8099917
(d) IP-10 and sustained response to treatment,degree of ﬁbrosis and degreeof inﬂammation. Footnote: data are presented as median and interquartile values of IP-10. Two-tailed P value
is signiﬁcant& 0.05.
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ethnic groups (51% Egyptians, 34% Europeans and 13.4% Sub-
Saharan Africans) (Asselah et al., 2012), 201 cases from Qatar
(Derbala et al., 2012) and 182 from Syria (Antaki et al., 2013), were
all analyzed for a single SNP, rs12979860 (except for Antaki et al.,
who studied rs8099917 and rs12979860). The current study provides
the largest study group to date with patients of the same ethnic
group with genotype 4 and studies 3 SNPs in correlation with the
cytokine IP-10.
To our knowledge, this is the ﬁrst study designed to investigate
the role of 3 SNPs of the IL28B gene, the rs12979860, rs11881222
and rs8099917 genotypes, in association with IP-10, as predictors
of SVR to PegIFN plus ribavirin in HCV-4 monoinfected patients of
Egyptian ethnicity.
Similar to Genotype 1, we found that rs12979860 and rs8099917
are strong pre-treatment predictors of SVR in patients with genotype
4 HCV infections. Moreover, we found a similar association with the
rs11881222 SNP, which was not previously investigated in Genotype 4.
A Marked linkage disequilibrium was noted between rs12979860 and
rs11881222, which is in agreement with a previous study by Rauch
et al. (2010), Rauch et al. (2010). We conﬁrm the association of the
following C, A and T alleles of 12979860, rs8099917 and rs11881222
with SVR in Genotype 4, respectively. Among Egyptians with genotype
4, the CC genotype appears to be a clear predictor of drug-induced
viral clearance events by 5-fold compared to the two- to three-fold
increase in the SVR rate in Genotype 1 (Thompson et al., 2010).
Furthermore, the AA and GG genotypes of rs8099917 and rs11881222,
respectively, are associated with a 4 to 5-fold increase in achieving
SVR. Similar to genotype 1, the major alleles of rs12979860 andrs11881222 had higher predictive values for SVR compared with
rs8099917. In support of our ﬁnding, with the role of C, A, and T
alleles of rs12979860, rs11881222 and rs8099917, respectively, in
achieving better response to treatment by univariate analysis, the
frequency of the CAT haplotype of these SNPs was double in our
patients who achieved SVR compared with NR. Additionally, the
current study revealed that the haplotype TGG, which had a signiﬁcant
risk of poor response, had the following risk alleles: T of rs12979860, G
of rs11881222 and G of rs8099917. Although only a few SNPs were
studied, we attempted to calculate the LD, which shows medium to
highest LD among the studied SNPs in this block. More SNPs within
this region could be included in further studies among our HCV
patients to clarify this LD association. A recent study by Pedergnana
et al. (2012) studied the LD for six SNPs of the IL-28B gene in Egyptian
populations and showed that the r2 value was 0.41 between
rs12979860 and rs8099917, which is congruent with our ﬁndings.
In agreement with previous reports on genotype 4 that inves-
tigated the rs12979860 SNP (Asselah et al., 2012; Cieśla et al.,
2012; El-Awady et al., 2012), we found that the tested IL28B SNPs
rs12979860 and rs8099917 were independent predictors of SVR.
The polymorphism rs12979860 had the highest predictive value of
SVR compared with rs11881222 and rs8099917, and the CC
genotype of rs12979860 had the highest predictive value in
genotype 4. Moreover, the multivariate regression analysis showed
that the rs12979860 SNP was the only SNP associated with
clearance, whereas the other SNPs ceased, conﬁrming that this
association was based on a single signal (Papastergiou et al., 2012).
The strong association between IL-28B polymorphisms and
response to antiviral therapy in patients with chronic HCV infection
M. Derbala et al. / Virology 444 (2013) 292–300298seems to be mediated by IFN-λ3, which is encoded by the IL-28B gene
(Balagopal et al., 2010). IFN-λ3 is a type III IFN that is involved in host
antiviral immunity and plays a role in immune-mediated and
treatment-associated clearance of HCV (Rallon et al., 2012). The role
of IFN-γ in inducing response to treatment was reconﬁrmed by Zhang
et al. (2011), who reported on the absence of correlations between the
levels of Th1/Th2 cytokines in the serum before and after IFN therapy,
while increasing serum IFN-γ levels induced by IFN treatment are
associated with a sustained response (Zhang et al., 2011). Alternatively,
Askarieh et al. (2010) suggested that IL28B variants are linked to
antiviral effectiveness by blocking the production or release of
infectious virions, rather than by clearing HCV infected cells.
The favorable TT genotype of rs8809917 was the predominant
among TVR, so extended course of therapy in these patients may
be helpful as, IFN-stimulated genes appear to be initially down-
regulated in patients with the rs8099917 TT genotype, which may
help to prevent desensitization and promote maximal induction of
IFN-stimulated genes (Honda et al., 2010).
Whereas, our ﬁndings showed that IL28B polymorphisms and
rapid viral clearance, as in genotype 1 (Chayama et al., 2011) remain
one of the strongest predictors of SVR in genotype 4, but the current
study highlights the importance and sensitivity of IP-10 as a biomarker
of poor response and its inverse correlation with the treatment
response.
Similar to Genotype 1, considering the high SVR rates among
HCV genotype-4 infected homozygous carriers of C/C at
rs12979860, G/G at rs11881222, and T/T at rs8099917 with low
IP-10 levels, these patients have the best chance of achieving
treatment-induced viral clearance (Lagging et al., 2011).
Recent research has shown that in patients with chronic HCV
infection, the majority of plasma IP-10 exists in a 2 amino-acid
truncated antagonist form, which inhibits the recruitment of T cells
and thus is responsible for the lack of desired antiviral effects of IP- 10
and could play an important role in pathology (Charles and Dustin,
2011).
Because of limitation in sample size, which may affect the
results, we recommend further studies in Genotype 4 including
larges sample to validate our results.Conclusions
In genotype 4, the IL28B rs12979860, rs8099917, and rs11881222
SNPs may have added value in the treatment algorithm because they
are the strongest predictors of response. We think that our study
provides additional evidence that IP-10 is a strong negative predictor
of response to Peg-IFN/Ribavirin therapy in HCV-4 monoinfected
patients, highlights the need to consider this factor in the individua-
lization of treatment, and augments the level of predictiveness of
IL28B polymorphisms for ﬁnal treatment outcome.
Considering the high SVR rates among HCV genotype-4
infected homozygous carriers of C/C at rs12979860, G/G at
rs11881222, and T/T at rs8099917 with low IP-10 levels, these
carriers have the best chance of achieving treatment-induced viral
clearance. The predominance of favorable rs8099917 genotypes TT,
rs11881222 genotypes AA and rs12979860 genotype CC may
explain the higher SVR among Egyptians.Patients and methods
Study design
This study was a retrospective-prospective cohort study. All
Egyptian, chronic HCV genotype 4 patients, who were followed in
the Hamad Medical Corporation outpatient clinic in the state ofQatar, received treatment between January and December 2010
and completed the 24-week post-treatment follow-up, were
included in the study (retrospective aspect). All patients were
treated subcutaneously, with 180 lg of Peginterferon -2a (Pegasys;
Hoffmann-LaRoche, Basel, Switzerland) once weekly and Ribavirin
(Copegus-; Hoffmann-La Roche, Basel, Switzerland) given at an
oral daily dose of 1000 mg (body weight £75 kg) or 1200 mg (body
weight ‡75 mg) for 48 weeks.
Polymorphisms (rs12979860, rs8099917, rs11881222 and
rs.81803142) in the IL28B genes were investigated in all patients.
The patients were classiﬁed according to the response to treat-
ment into responders (control group) and non-responders (case
group). All patients provided written informed consent according
to the Declaration of Helsinki of 1979.
Patient selection
The study recruited 159 chronic HCV-genotype 4 patients.
Nationalities other than Egyptian were excluded to avoid ethnic-
speciﬁc variability of response to treatment. Chronic HCV infection
was conﬁrmed by positive serology for anti-HCV, active viral
replication by the detection of HCV-RNA in the serum and
histological ﬁndings of chronic active hepatitis according to the
Scheuer Score. The necroinﬂammatory and ﬁbrosis scores were
assigned based on the Scheuer scoring system from 0 to 4. Patients
were further subdivided into mild ﬁbrosis (stages I & II) and
cirrhosis (stages III & IV). None of the patients in our study
exhibited serological evidence of autoimmune liver disease or
inheritable disorders, such as hemochromatosis, Wilson's disease,
a history of alcoholism or drug abuse. Hepatocellular carcinoma
was excluded using α-fetoprotein testing and ultrasound scanning.
Anti-HCV tests were performed using a commercial ELISA kit
(Axsym 3.0; Abbott Laboratories, Chicago, IL, USA). All patients
were conﬁrmed to be HCV-G4 using the Inno-LiPA HCV II assay
(Innogenetics, Inc., Alpharetta, GA, USA). The monitoring of serum
HCV RNA levels was performed using Amplicor (version 2.0,
Hoffmann-La Roche) with a minimum detection limit of 50 IU/mL.
All patients were treated with pegylated interferon once a week and
oral ribavirin at a daily dose of 1000 mg (body weight 475 kg) or
1200 mg (body weight o75 kg) for 48 weeks. Patients with
positive serology for schistosomiasis were treated with praziquantel
(biltricide) prior to antiviral therapy.
The primary efﬁcacy outcome was a sustained virological
response (SVR), which was deﬁned as undetectable HCV RNA 24
weeks after the end of the treatment. Relapse was deﬁned as the
reappearance of HCV RNA during follow-up in subjects with
previous end-of-treatment response (ETR), which is undetectable
serum HCV RNA at the end of therapy, whereas Rapid Virological
Response (RVR) is undetectable hepatitis C virus after 4 weeks of
treatment, Early Virological Response( EVR) is undetectable or
dropped viral load by 2 log after 12 weeks of HCV treatment and a
transient viral response (TVR) was deﬁned as a reappearance of
HCV RNA in serum after treatment was discontinued in a patient
who had undetectable HCV RNA during the therapy or on comple-
tion of the therapy. A non-viral response (NVR) was deﬁned as cases
with detectable viremia after and during treatment.
Genotyping of 4 polymorphism variants (SNPs) of IL28B
The SNP selection was performed following the work of Ito
et al. (2011), and genotyping was performed as published pre-
viously by Rizk and Derbala (2012). Genomic DNA was extracted
from EDTA whole blood samples using the QiaAmp DNA Blood
Mini Kit #51166 (Qiagen GmbH, Hilden, Germany) followed by
assessment of DNA concentration using a Nanodrop spectrophot-
ometer. Polymorphisms of the studied SNPs were analyzed by the
M. Derbala et al. / Virology 444 (2013) 292–300 2995′ nuclease assay using a TaqMan MGB probe assay. The primers
and TaqMan MGB probes of these polymorphisms were provided
by the assay on-demand ™ service by Applied Biosystems. The 5′
nuclease assay was performed using 20 ng genomic DNA, 1X
TaqMan Universal PCR Master Mix (Applied Biosystems), and 1X
primer/probe mix using the appropriate conditions for ampliﬁca-
tion according to the manufacturer's instructions. Negative con-
trols and non-template controls were included in each run. The
reaction was performed using an ABI 7500 (Applied Biosystems,
Foster City, CA) in the Biomedical Labs-Health Sciences
Department-CAS-at University of Qatar, Doha-Qatar.
IP-10 Assay
For the detection of serum IP-10, the human cytokine multiplex
immunoassay kit (MPXHCYTO‐60K‐06) was used according to the
manufacturer's instructions from Millipore (Merck Millipore, Bill-
erica, MA, USA). The percentage intra- and inter-assay CV of the
assay was 4.6–13.8 and 3.7–17.2, respectively. The assay was
performed using a Luminex 200 (Austin, TX, USA).
Statistical analysis
Continuous data are expressed as the mean and standard
deviation for normalized distributed variables and by the median
and interquartile for non-normalized distributed variables. Cate-
gorical data are presented in the form of number and percentage.
All statistical analyses were performed using the SPSS program for
Windows (version 20 statistical software; Texas instruments, IL,
USA), and the Golden Helix SNP and Variation Suite (SVS 7.6 soft-
ware; Bozeman, MT, USA) were used for genetic analysis. Graph-
Pad Prism (version 6, for Mac, GraphPad Software, La Jolla
California USA) was used for graphic representations. Genotype
distributions and allele frequencies between the study groups
were compared by constructing 22 contingency tables, x2, and/
or Fisher exact test corrected for Bonferroni adjustment for the
number of SNPs. The Hardy-Weinberg equilibrium (HWE) was
calculated using the chi-squared test to determine the genotype
distribution in all study subjects. The odds ratios (ORs), 95%
conﬁdence intervals (CIs), and corresponding P values for the
samples were analyzed by logistic regression analysis. The ORs
were computed using the major homozygous allele as the refer-
ence group unless otherwise stated. The positive predictive value
(PPV) was calculated for the major allele for good therapy
response where PPV¼(ntrue positive/ntrue positive+nfalse positive).
Pairwise linkage disequilibrium coefﬁcients (D′) and haplotype
frequency were estimated using the SVS 7.6 software. A two-tailed
P-valueo0.05 was considered statistically signiﬁcant.Acknowledgments
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